<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35958821</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2314-6141</ISSN><JournalIssue CitedMedium="Internet"><Volume>2022</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>BioMed research international</Title><ISOAbbreviation>Biomed Res Int</ISOAbbreviation></Journal><ArticleTitle>IgA-Type Enterovirus Antibodies Are Increased among Adults and Children with Recently Diagnosed Type 1 Diabetes.</ArticleTitle><Pagination><StartPage>7603062</StartPage><MedlinePgn>7603062</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">7603062</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2022/7603062</ELocationID><Abstract><AbstractText>Enteroviruses (EV) are among the leading environmental triggers of childhood-onset type 1 diabetes (T1D). Our aim was to determine the prevalence of antibodies against EV and their association with T1D in different age groups (<i>n</i> = 62), including young adults, and to compare these data with results from HLA-matched control participants (<i>n</i> = 62). IgA, IgG, and IgM antibodies against EV were detected. IgA EV antibodies were present in 46.8% of participants with T1D (median level 10.9 EIU) and in 11.3% of controls (median level 3.4 EIU). IgA EV positivity and higher level of IgA EV antibodies were both significant risk factors for T1D (odds ratio (OR) 8.33; 95% confidence interval (CI) 2.52-27.6; <i>p</i> = 0.0005 and OR 1.04; 95% CI 1.01-1.06; <i>p</i> = 0.0105, respectively). Importantly, the prevalence of IgA EV antibodies in the subgroups of both children and young adults was also significantly different between participants with T1D and their matched controls (<i>p</i> = 0.0089 and <i>p</i> = 0.0055, respectively). Such differences were not seen for IgG and IgM EV antibodies. However, IgG EV antibodies were associated with 65 kDa glutamic acid decarboxylase antibodies, but not with zinc transporter 8 and protein tyrosine phosphatase IA2 antibodies. The genotype frequency of PTPN22 (rs2476601) and IFIH1 (rs1990760) was not associated with EV positivity. This study showed that EV infections may be an important disease-promoting factor of T1D not only in childhood-onset but also in adult-onset T1D. However, to further confirm this association, direct virological studies are needed in the latter T1D group.</AbstractText><CopyrightInformation>Copyright © 2022 Kristi Alnek et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alnek</LastName><ForeName>Kristi</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-7774-2908</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Institute of Bio- and Translational Medicine, University of Tartu, 19 Ravila, Tartu 50411, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talja</LastName><ForeName>Ija</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Immunology, Institute of Bio- and Translational Medicine, University of Tartu, 19 Ravila, Tartu 50411, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laht</LastName><ForeName>Brita</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Immunology, Institute of Bio- and Translational Medicine, University of Tartu, 19 Ravila, Tartu 50411, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metsküla</LastName><ForeName>Kaja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Immunology, Institute of Bio- and Translational Medicine, University of Tartu, 19 Ravila, Tartu 50411, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandel</LastName><ForeName>Maire</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology, Institute of Bio- and Translational Medicine, University of Tartu, 19 Ravila, Tartu 50411, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reppo</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Institute of Clinical Medicine, University of Tartu, 8 L. Puusepa, Tartu 50406, Estonia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Clinic of Tartu University Hospital, 8 L. Puusepa, Tartu 50406, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lubi</LastName><ForeName>Maire</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Institute of Clinical Medicine, University of Tartu, 8 L. Puusepa, Tartu 50406, Estonia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Clinic of Tartu University Hospital, 8 L. Puusepa, Tartu 50406, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uibo</LastName><ForeName>Raivo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-2298-1300</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Institute of Bio- and Translational Medicine, University of Tartu, 19 Ravila, Tartu 50411, Estonia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biomed Res Int</MedlineTA><NlmUniqueID>101600173</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.48</RegistryNumber><NameOfSubstance UI="C516765">PTPN22 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.48</RegistryNumber><NameOfSubstance UI="D054596">Protein Tyrosine Phosphatase, Non-Receptor Type 22</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="Y">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054596" MajorTopicYN="N">Protein Tyrosine Phosphatase, Non-Receptor Type 22</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that there is no conflict of interest regarding the publication of this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>12</Day><Hour>3</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35958821</ArticleId><ArticleId IdType="pmc">PMC9357813</ArticleId><ArticleId IdType="doi">10.1155/2022/7603062</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DiMeglio L. A., Evans-Molina C., Oram R. A. Type 1 diabetes. The Lancet . 2018;391(10138):2449–2462. doi: 10.1016/S0140-6736(18)31320-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31320-5</ArticleId><ArticleId IdType="pmc">PMC6661119</ArticleId><ArticleId IdType="pubmed">29916386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilonen J., Kiviniemi M., Lempainen J., et al. Genetic susceptibility to type 1 diabetes in childhood-estimation of HLA class II associated disease risk and class II effect in various phases of islet autoimmunity. Pediatric Diabetes . 2016;17(S22):8–16. doi: 10.1111/pedi.12327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pedi.12327</ArticleId><ArticleId IdType="pubmed">27411431</ArticleId></ArticleIdList></Reference><Reference><Citation>Nekoua M. P., Alidjinou E. K., Hober D. Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus. Nature Reviews Endocrinology . 2022;18(8):503–516. doi: 10.1038/s41574-022-00688-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-022-00688-1</ArticleId><ArticleId IdType="pmc">PMC9157043</ArticleId><ArticleId IdType="pubmed">35650334</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyöty H. Viruses in type 1 diabetes. Pediatric Diabetes . 2016;17:56–64. doi: 10.1111/pedi.12370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pedi.12370</ArticleId><ArticleId IdType="pubmed">27411438</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyöty H., Leon F., Knip M. Developing a vaccine for type 1 diabetes by targeting coxsackievirus B. Expert Review of Vaccines . 2018;17(12):1071–1083. doi: 10.1080/14760584.2018.1548281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2018.1548281</ArticleId><ArticleId IdType="pubmed">30449209</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyöty H., Taylor K. The role of viruses in human diabetes. Diabetologia . 2002;45(10):1353–1361.</Citation><ArticleIdList><ArticleId IdType="pubmed">12378375</ArticleId></ArticleIdList></Reference><Reference><Citation>Hober D., Sane F. Enteroviral pathogenesis of type 1 diabetes. Discovery Medicine . 2010;10(51):151–160.</Citation><ArticleIdList><ArticleId IdType="pubmed">20807476</ArticleId></ArticleIdList></Reference><Reference><Citation>Hober D., Sauter P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. Nature Reviews. Endocrinology . 2010;6(5):279–289. doi: 10.1038/nrendo.2010.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2010.27</ArticleId><ArticleId IdType="pubmed">20351698</ArticleId></ArticleIdList></Reference><Reference><Citation>Viskari H., Ludvigsson J., Uibo R., et al. Relationship between the incidence of type 1 diabetes and enterovirus infections in different European populations: results from the EPIVIR project. Journal of Medical Virology . 2004;72(4):610–617. doi: 10.1002/jmv.20033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20033</ArticleId><ArticleId IdType="pubmed">14981763</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig M. E., Nair S., Stein H., Rawlinson W. D. Viruses and type 1 diabetes: a new look at an old story. Pediatric Diabetes . 2013;14(3):149–158. doi: 10.1111/pedi.12033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pedi.12033</ArticleId><ArticleId IdType="pubmed">23517503</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvani G., Fousteri G. PTPN22 and islet-specific autoimmunity: what have the mouse models taught us? World Journal of Diabetes . 2017;8(7):330–336. doi: 10.4239/wjd.v8.i7.330.</Citation><ArticleIdList><ArticleId IdType="doi">10.4239/wjd.v8.i7.330</ArticleId><ArticleId IdType="pmc">PMC5507829</ArticleId><ArticleId IdType="pubmed">28751955</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanter M., Sork H., Tuomela S., Flodström-Tullberg M. Genetic and environmental interaction in type 1 diabetes: a relationship between genetic risk alleles and molecular traits of enterovirus infection? Current Diabetes Reports . 2019;19(9, article 1192):p. 82. doi: 10.1007/s11892-019-1192-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11892-019-1192-8</ArticleId><ArticleId IdType="pmc">PMC6689284</ArticleId><ArticleId IdType="pubmed">31401790</ArticleId></ArticleIdList></Reference><Reference><Citation>Insel R. A., Dunne J. L., Atkinson M. A., et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care . 2015;38(10):1964–1974. doi: 10.2337/dc15-1419.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc15-1419</ArticleId><ArticleId IdType="pmc">PMC5321245</ArticleId><ArticleId IdType="pubmed">26404926</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S. K., Ma C. S., Fourlanos S., Greenfield J. R. Autoantibody-negative type 1 diabetes: a neglected subtype. Trends in Endocrinology &amp; Metabolism . 2021;32(5):295–305. doi: 10.1016/j.tem.2021.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2021.02.001</ArticleId><ArticleId IdType="pubmed">33712367</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association. Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care in Diabetes—2015. Diabetes Care . 2015;38(Supplement 1):S8–S16.</Citation><ArticleIdList><ArticleId IdType="pubmed">25537714</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikk M.-L., Kiviniemi M., Laine A.-P., et al. The HLA-B∗39 allele increases type 1 diabetes risk conferred by HLA-DRB1 ∗04:04-DQB1∗03:02 and HLA-DRB1 ∗08-DQB1∗04 class II haplotypes. Human Immunology . 2014;75(1):65–70. doi: 10.1016/j.humimm.2013.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2013.09.008</ArticleId><ArticleId IdType="pubmed">24055898</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiviniemi M., Hermann R., Nurmi J., et al. A high-throughput population screening system for the estimation of genetic risk for type 1 diabetes: an application for the TEDDY (The Environmental Determinants of Diabetes in the Young) study. Diabetes Technology &amp; Therapeutics . 2007;9(5):460–472. doi: 10.1089/dia.2007.0229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/dia.2007.0229</ArticleId><ArticleId IdType="pubmed">17931054</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampasona V., Pittman D. L., Williams A. J., et al. Islet autoantibody standardization program 2018 workshop: interlaboratory comparison of glutamic acid decarboxylase autoantibody assay performance. Clinical Chemistry . 2019;65(9):1141–1152. doi: 10.1373/clinchem.2019.304196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2019.304196</ArticleId><ArticleId IdType="pmc">PMC8936135</ArticleId><ArticleId IdType="pubmed">31409598</ArticleId></ArticleIdList></Reference><Reference><Citation>Douroudis K., Prans E., Haller K., et al. Protein tyrosine phosphatase non-receptor type 22 gene variants at position 1858 are associated with type 1 and type 2 diabetes in Estonian population. Tissue Antigens . 2008;72(5):425–430. doi: 10.1111/j.1399-0039.2008.01115.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0039.2008.01115.x</ArticleId><ArticleId IdType="pubmed">18764813</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste M. S., Maher K., Kilpatrick D. R., Flemister M. R., Brown B. A., Pallansch M. A. Typing of human enteroviruses by partial sequencing of VP1. Journal of Clinical Microbiology . 1999;37(5):1288–1293. doi: 10.1128/JCM.37.5.1288-1293.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.37.5.1288-1293.1999</ArticleId><ArticleId IdType="pmc">PMC84754</ArticleId><ArticleId IdType="pubmed">10203472</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeharju K., Lönnrot M., Kimpimäki T., et al. Enterovirus antibody levels during the first two years of life in prediabetic autoantibody-positive children. Diabetologia . 2001;44(7):818–823. doi: 10.1007/s001250100560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001250100560</ArticleId><ArticleId IdType="pubmed">11508265</ArticleId></ArticleIdList></Reference><Reference><Citation>Panarina M., Kisand K., Alnek K., Heilman K., Peet A., Uibo R. Interferon and interferon-inducible gene activation in patients with type 1 diabetes. Scandinavian Journal of Immunology . 2014;80(4):283–292. doi: 10.1111/sji.12204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12204</ArticleId><ArticleId IdType="pubmed">24965593</ArticleId></ArticleIdList></Reference><Reference><Citation>Salur L., Oikarinen S., Tauriainen S., Mandel M., Hyöty H., Uibo R. Enterovirus infections in young infants: are children still protected by maternal antibodies? Human Vaccines . 2011;7(9):966–971. doi: 10.4161/hv.7.9.16082.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.7.9.16082</ArticleId><ArticleId IdType="pubmed">21860257</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen K., Sadeharju K., Lönnrot M., et al. Enterovirus infections are associated with the induction of β-cell autoimmunity in a prospective birth cohort study. Journal of Medical Virology . 2003;69(1):91–98. doi: 10.1002/jmv.10260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.10260</ArticleId><ArticleId IdType="pubmed">12436483</ArticleId></ArticleIdList></Reference><Reference><Citation>Imagawa A., Hanafusa T., Makino H., Miyagawa J.-I., Juto P. High titres of IgA antibodies to enterovirus in fulminant type-1 diabetes. Diabetologia . 2005;48(2):290–293. doi: 10.1007/s00125-004-1624-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-004-1624-z</ArticleId><ArticleId IdType="pubmed">15654603</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K., Ye F., Chen Y., et al. Association between enterovirus infection and type 1 diabetes risk: a meta-analysis of 38 case-control studies. Frontiers in Endocrinology . 2021;12, article 706964 doi: 10.3389/fendo.2021.706964.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.706964</ArticleId><ArticleId IdType="pmc">PMC8453141</ArticleId><ArticleId IdType="pubmed">34557158</ArticleId></ArticleIdList></Reference><Reference><Citation>Pabst O., Slack E. IgA and the intestinal microbiota: the importance of being specific. Mucosal Immunology . 2020;13(1):12–21. doi: 10.1038/s41385-019-0227-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41385-019-0227-4</ArticleId><ArticleId IdType="pmc">PMC6914667</ArticleId><ArticleId IdType="pubmed">31740744</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehik K., Lynch K. F., Wong M. C., et al. Prospective virome analyses in young children at increased genetic risk for type 1 diabetes. Nature Medicine . 2019;25(12, article 667):1865–1872. doi: 10.1038/s41591-019-0667-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0667-0</ArticleId><ArticleId IdType="pmc">PMC6898786</ArticleId><ArticleId IdType="pubmed">31792456</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K. W., Horton J. L., Pang C. N. I., et al. Higher abundance of enterovirus A species in the gut of children with islet autoimmunity. Scientific Reports . 2019;9(1, article 1749) doi: 10.1038/s41598-018-38368-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-38368-8</ArticleId><ArticleId IdType="pmc">PMC6370883</ArticleId><ArticleId IdType="pubmed">30741981</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeharju K., Knip M., Virtanen S. M., et al. Maternal antibodies in breast milk protect the child from enterovirus infections. Pediatrics . 2007;119(5):941–946. doi: 10.1542/peds.2006-0780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2006-0780</ArticleId><ArticleId IdType="pubmed">17473095</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyöty H., Huupponen T., Leinikki P. Humoral immunity against viral antigens in insulin-dependent diabetes mellitus (IDDM): altered IgA class immune response against mumps virus. Clinical and Experimental Immunology . 1985;60(1):139–144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1577011</ArticleId><ArticleId IdType="pubmed">4006299</ArticleId></ArticleIdList></Reference><Reference><Citation>Real-Fernández F., Gallo A., Nuti F., et al. Cross-reactive peptide epitopes of enterovirus coxsackie B4 and human glutamic acid decarboxylase detecting antibodies in latent autoimmune diabetes in adults versus type 1 diabetes. Clinica Chimica Acta . 2021;515:73–79. doi: 10.1016/j.cca.2021.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2021.01.002</ArticleId><ArticleId IdType="pubmed">33422493</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynn J. R., Moss P. A. H. Systematic analysis of infectious disease outcomes by age shows lowest severity in school-age children. Scientific Data . 2020;7(1):p. 329. doi: 10.1038/s41597-020-00668-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-020-00668-y</ArticleId><ArticleId IdType="pmc">PMC7566589</ArticleId><ArticleId IdType="pubmed">33057040</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawyer M. H. Enterovirus infections: diagnosis and treatment. Seminars in Pediatric Infectious Diseases . 2002;13(1):40–47. doi: 10.1053/spid.2002.29756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/spid.2002.29756</ArticleId><ArticleId IdType="pubmed">12118843</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeharju K., Knip M., Hiltunen M., Åkerblom H. K., Hyöty H. The HLA-DR phenotype modulates the humoral immune response to enterovirus antigens. Diabetologia . 2003;46(8):1100–1105. doi: 10.1007/s00125-003-1157-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-003-1157-x</ArticleId><ArticleId IdType="pubmed">12845430</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig M. E., Howard N. J., Silink M., Rawlinson W. D. Reduced frequency of HLA DRB1∗03-DQB1∗02 in children with type 1 diabetes associated with enterovirus RNA. The Journal of Infectious Diseases . 2003;187(10):1562–1570. doi: 10.1086/374742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/374742</ArticleId><ArticleId IdType="pubmed">12721936</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermann R., Turpeinen H., Laine A. P., et al. HLA DR-DQ-encoded genetic determinants of childhood-onset type 1 diabetes in Finland: an analysis of 622 nuclear families. Tissue Antigens . 2003;62(2):162–169. doi: 10.1034/j.1399-0039.2003.00071.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1399-0039.2003.00071.x</ArticleId><ArticleId IdType="pubmed">12889996</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte B. M., Gielen P. R., Kers-Rebel E. D., et al. Enterovirus exposure uniquely discriminates type 1 diabetes patients with a homozygous from a heterozygous melanoma differentiation-associated protein 5/interferon induced with helicase C domain 1A946T genotype. Viral Immunology . 2016;29(7):389–397. doi: 10.1089/vim.2015.0140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2015.0140</ArticleId><ArticleId IdType="pubmed">27482829</ArticleId></ArticleIdList></Reference><Reference><Citation>Witsø E., Cinek O., Tapia G., et al. Genetic determinants of enterovirus infections: polymorphisms in type 1 diabetes and innate immune genes in the MIDIA study. Viral Immunology . 2015;28(10):556–563. doi: 10.1089/vim.2015.0067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2015.0067</ArticleId><ArticleId IdType="pubmed">26485223</ArticleId></ArticleIdList></Reference><Reference><Citation>Saarinen N. V. V., Lehtonen J., Veijola R., et al. Multiplexed high-throughput serological assay for human enteroviruses. Microorganisms . 2020;8(6):p. 963. doi: 10.3390/microorganisms8060963.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms8060963</ArticleId><ArticleId IdType="pmc">PMC7355947</ArticleId><ArticleId IdType="pubmed">32604930</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>